Medicure Inc V.MPH

Alternate Symbol(s): MCUJF

Healthcare Biotechnology

Medicure Inc. is a Canada-based pharmaceutical company. The Company is focused on the development and commercialization of therapies for the United States cardiovascular market. The focus of the Company is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company’s United States subsidiary, Medicure Pharma Inc. The Company also operates Marley Drug, Inc. (Marley Drug), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

TSXV:MPH - Post by User

Medicure Inc > New Article

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Dec 08, 2022 7:29pm

174 Views

Post# 35160616

RE:RE:RE:New Article

CEO buys another $14,140 worth of stock as he continues to add to his holdings.

prophetoffactz wrote: CEO buys another $16,720 worth of stock further adding to his recent buys.

$16,720
+15,200 vol
$1.10 each

prophetoffactz wrote: The CEO has now bought >$71,000 worth of shares in recent months having added another $11,000 last Friday.

prophetoffactz wrote: As the CEO continues to buy shares here's a new article suggesting why. Some of the top clinicians in the world are involved with a study about to commence in Q4. Approval could be a game-changer. MPH has already received a Priority Review Voucher that could be worth US$100-US$200 million.

Pg. 20:
Insights Magazine - BIOTECanada (biotech.ca)